ARTICLE | Company News
Savient resubmits Krystexxa BLA
March 16, 2010 1:36 AM UTC
Savient Pharmaceuticals Inc. (NASDAQ:SVNT) resubmitted a BLA to FDA for Krystexxa pegloticase to treat chronic refractory gout. Savient said the resubmission addresses issues raised by FDA in a July 2...